Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secretion of IL1 by Dedifferentiated Melanoma Cells Inhibits JAK1-STAT3-Driven Actomyosin Contractility of Lymph Node Fibroblastic Reticular Cells.
Rovera C, Berestjuk I, Lecacheur M, Tavernier C, Diazzi S, Pisano S, Irondelle M, Mallavialle A, Albrengues J, Gaggioli C, Girard CA, Passeron T, Deckert M, Tartare-Deckert S, Prod'homme V. Rovera C, et al. Among authors: passeron t. Cancer Res. 2022 May 3;82(9):1774-1788. doi: 10.1158/0008-5472.CAN-21-0501. Cancer Res. 2022. PMID: 35502542 Free article.
Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma.
Zerhouni M, Martin AR, Furstoss N, Gutierrez VS, Jaune E, Tekaya N, Beranger GE, Abbe P, Regazzetti C, Amdouni H, Driowya M, Dubreuil P, Luciano F, Jacquel A, Tulic MK, Cluzeau T, O'Hara BP, Ben-Sahra I, Passeron T, Benhida R, Robert G, Auberger P, Rocchi S. Zerhouni M, et al. Among authors: passeron t. Cancer Res. 2021 Jul 15;81(14):3806-3821. doi: 10.1158/0008-5472.CAN-20-2114. Epub 2021 Jun 7. Cancer Res. 2021. PMID: 34099492
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma.
Berestjuk I, Lecacheur M, Carminati A, Diazzi S, Rovera C, Prod'homme V, Ohanna M, Popovic A, Mallavialle A, Larbret F, Pisano S, Audebert S, Passeron T, Gaggioli C, Girard CA, Deckert M, Tartare-Deckert S. Berestjuk I, et al. Among authors: passeron t. EMBO Mol Med. 2022 Feb 7;14(2):e11814. doi: 10.15252/emmm.201911814. Epub 2021 Dec 27. EMBO Mol Med. 2022. PMID: 34957688 Free PMC article.
Inhibition of melanogenesis by the antidiabetic metformin.
Lehraiki A, Abbe P, Cerezo M, Rouaud F, Regazzetti C, Chignon-Sicard B, Passeron T, Bertolotto C, Ballotti R, Rocchi S. Lehraiki A, et al. Among authors: passeron t. J Invest Dermatol. 2014 Oct;134(10):2589-2597. doi: 10.1038/jid.2014.202. Epub 2014 Apr 22. J Invest Dermatol. 2014. PMID: 24756109 Free article.
Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.
Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, Botton T, Ronco C, Abbe P, Amdouni H, Passeron T, Hofman V, Mograbi B, Dabert-Gay AS, Debayle D, Alcor D, Rabhi N, Annicotte JS, Héliot L, Gonzalez-Pisfil M, Robert C, Moréra S, Vigouroux A, Gual P, Ali MMU, Bertolotto C, Hofman P, Ballotti R, Benhida R, Rocchi S. Cerezo M, et al. Among authors: passeron t. Cancer Cell. 2016 Jun 13;29(6):805-819. doi: 10.1016/j.ccell.2016.04.013. Epub 2016 May 26. Cancer Cell. 2016. PMID: 27238082 Free article.
E2F1 inhibition mediates cell death of metastatic melanoma.
Rouaud F, Hamouda-Tekaya N, Cerezo M, Abbe P, Zangari J, Hofman V, Ohanna M, Mograbi B, El-Hachem N, Benfodda Z, Lebeau A, Tulic MK, Hofman P, Bertolotto C, Passeron T, Annicotte JS, Ballotti R, Rocchi S. Rouaud F, et al. Among authors: passeron t. Cell Death Dis. 2018 May 1;9(5):527. doi: 10.1038/s41419-018-0566-1. Cell Death Dis. 2018. PMID: 29743521 Free PMC article.
354 results